ArticleArchives of orthopaedic and trauma surgery2026
Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence.
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGiant cell tumor of bone (GCTB) is a locally aggressive tumor with a considerable risk of recurrence, but reliable predictive markers are limited. High-temperature requirement A serine peptidase 1 (HtrA1) has been implicated in the progression of several cancers and may also play a role in GCTB recurrence. MATERIALS AND
methodsThis retrospective study included 34 patients with GCTB treated with curettage between 2002 and 2016. HtrA1 expression was evaluated separately in giant cells (GC) and mononuclear cells (MNC) using immunohistochemistry. Based on high or low expression in each cell type, patients were categorized into four expression patterns: High GC / High MNC, High GC / Low MNC, Low GC / High MNC, and Low GC / Low MNC. Clinical data, including recurrence status and time to recurrence, were analyzed.
resultsThe High GC / Low MNC group showed the highest recurrence rate at 71.4%, compared with 28.6% in the High GC / High MNC group and 31.6% in the Low GC / Low MNC group. No recurrence was observed in the Low GC / High MNC group, which included only one patient. The High GC / Low MNC group showed a non-significant trend toward higher recurrence compared with all other groups combined, with a similar trend toward shorter recurrence-free survival.
conclusionHtrA1 expression patterns in GCTB may provide preliminary insight into recurrence risk. Although no statistically significant association was demonstrated, the observed trends suggest potential prognostic relevance and warrant validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.